MPM BioImpact | Activity | F4

Introducing F4 Champions, a new accelerator for founders at the earliest stage.F4 Champions for early-stage foundersEnrollment closesAugust 2Learn more

Team Portfolio Raise Champions Essays

F4/MPM BioImpact/Activity

MPM BioImpact Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Investment

Founded and led a $50M seed financing for K2 Therapeutics, a Singapore-based biotech spun out of MPM BioImpact.

K2 Therapeutics

K2 Therapeutics MPM BioImpact

technode.globalAUG 11, 2026

AUG 11, 2026

Exit

Portfolio company Firefly Bio was acquired by Johnson & Johnson to advance next-generation oncology innovation.

Firefly Bio

Firefly Bio MPM BioImpact

mpmbioimpact.comJUL 29, 2026

JUL 29, 2026

Investment

Participated as an existing investor in Crossbow Therapeutics' $77M Series B financing, co-led by Taiho Ventures and Arkin Bio Capital.

Crossbow Therapeutics

Crossbow Therapeutics MPM BioImpact

businesswire.comMAR 18, 2026

MAR 18, 2026

Exit

Portfolio company Orna Therapeutics agreed to be acquired by Eli Lilly for up to $2.4B to advance in vivo CAR-T cell therapies.

Orna Therapeutics

Orna Therapeutics MPM BioImpact

prnewswire.comFEB 9, 2026

FEB 9, 2026

Milestone

Portfolio company Aktis Oncology priced an upsized IPO at $18/share, raising approximately $318M gross proceeds and began trading on Nasdaq as AKTS.

Aktis Oncology

Aktis Oncology MPM BioImpact

globenewswire.comJAN 9, 2026

JAN 9, 2026

Investment

Led a PIPE financing of up to $306.9M in DBV Technologies to advance the Viaskin Peanut Patch toward BLA submission and US launch.

DBV Technologies

DBV Technologies MPM BioImpact

globenewswire.comMAR 28, 2025

MAR 28, 2025

Team Change

Appointed Brian Shuster as Entrepreneur Partner and promoted Rami Rahal to Partner.

Brian Shuster joined as Entrepreneur Partner; Rami Rahal promoted to Partner

mpmbioimpact.comJAN 8, 2025

JAN 8, 2025

Investment

Participated in Aktis Oncology's oversubscribed $175M Series B financing to advance its radiopharmaceutical pipeline.

Aktis Oncology

Aktis Oncology MPM BioImpact

prnewswire.comSEP 30, 2024

SEP 30, 2024

Investment

Co-led Reunion Neuroscience's $103M Series A financing alongside Novo Holdings to advance RE104 for postpartum depression.

Reunion Neuroscience

Reunion Neuroscience MPM BioImpact

globenewswire.comMAY 2, 2024

MAY 2, 2024